Lexicon Pharmaceuticals (LXRX) PT Raised to $6 at Leerink Partners

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. TMUS
7. SPY
8. CVS
9. UNH
10. AXP

Go back to Lexicon Pharmaceuticals (LXRX) PT Raised to $6 at Leerink Partners

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe

October 16, 2024 4:35 PM EDT

THE WOODLANDS, Texas, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Viatris Inc. (Nasdaq: VTRS) has obtained an exclusive license from Lexicon to commercialize sotagliflozin outside of the United States and Europe in all indications. Lexicon retains sole commercialization rights for sotagliflozin in all indications in the United States and Europe.

Sotagliflozin was approved by the U.S. Food and Drug Administration in May 2023 to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart... More

Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe

October 16, 2024 4:35 PM EDT

Continues to Expand Viatris' Innovative Portfolio in Cardiovascular Diseases Leverages Viatris' Unique Global Infrastructure and ExpertiseIncludes Opportunities to Leverage the Potential of Sotagliflozin to Additional Indications

PITTSBURGH, Oct. 16, 2024 /PRNewswire/ -- Viatris... More